RNXT Stock Analysis: Buy, Sell, or Hold?
RNXT - RenovoRx, Inc. Common Stock
$0.84
-0.03 (-3.46%)
▼
5d:
-11.5%
30d:
-25.66%
90d:
-6.57%
WAIT
LOW Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 21, 2026
21d
Get Alerted When RNXT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RNXT is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RNXT is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNXT is currently trading at $0.84, which is considered oversold relative to its 30-day fair value range of $0.91 to $1.07.
Technical Outlook: Technically, RNXT is showing sideways momentum. The price is currently testing key support at $0.83. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.88 (+718.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNXT is showing sideways momentum. The price is currently testing key support at $0.83. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.88 (+718.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.91 -
$1.07
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 718.5% below Wall St target ($6.88)
- WARNING: Recommendation downgraded due to -11.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.91 -
$1.07
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.83
Resistance Level
$1.04
Current Trend
Sideways
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.00
Wall Street Target
$6.88
(+718.5%)
Revenue Growth (YoY)
453.5%
Share & Embed Analysis
Last updated: April 29, 2026 6:07 AM ET
Data refreshes hourly during market hours. Next update: 7:07 AM
Data refreshes hourly during market hours. Next update: 7:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNXT showing a specific setup today?
Insider Activity (6 Months)
8
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ramtin Agah
BUY
10000 shares
2026-01-21
Ramtin Agah
BUY
9795 shares
2025-12-31
Ramtin Agah
BUY
205 shares
2025-12-30
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 55 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 53 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$173 | 62 BUY |
|
KRYS
Krystal Biotech Inc |
STRONG BUY
11 analysts |
$315 | 67 BUY |
